GregFolin

$ISWH Record Oversold as Telehealth Segment Gets Traction

OTC:ISWH   None
ISWH has held support four days in a row following the announcement of the Company's establishment of a fully operational Telehealth subsidiary that's already seeing commercial-stage activity.

The float is small and shorts have been active, suggesting some strong squeeze potential if momentum gets rolling.

There’s a new way of doing business in the healthcare space, and companies like ISW Holdings Inc (OTCMKTS:ISWH) have an inside edge on that emerging competitive landscape.

The company has already demonstrated rapid topline growth in its home healthcare operations with five consecutive quarters of sharp sequential growth. Its most recent quarter showed revenues of nearly $250K, representing year-over-year growth of 79% (and 244% for the first half of the year) compared to comparable periods in 2019.

But this trend seems more likely to accelerate rather than taper off based on our simple analysis. A big factor in that outlook – again our own analysis based on judgement and data from the company – is that it is expanding, with the recent establishment, licensing, and ramp-up of its new Telecare subsidiary, which recently received its license from the State of Texas under Chapter 142 of the Texas Health and Safety Code to operate in Texas.

According to a recent release from ISWH, the Telecare referral intake process is fully electronic, with provider referrals opening a client relationship, coordinating care with providers, logging all consents, and assigning a home health caretaker, all achieved entirely electronically. Within twelve hours, an on-site assessment with a registered nurse is conducted, and full care services begin within 24 hours. The Telecare team is growing, and the Company intends to ramp up service across the state and to extend its service area into additional states over coming months.

In other words, ISWH’s Telecare subsidiary is a telehealth efficiency solution that is now operational and starting to drive additional growth for the company in Q4.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.